Zobrazeno 1 - 10
of 79
pro vyhledávání: '"K, De Beule"'
Publikováno v:
Mycoses. 35:1-8
Oral candidosis in neonates and children is a common infection which occurs often during the first few months after birth, but occasionally also in older children with certain predisposing factors. In neonates, oral candidosis is usually benign, alth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2124bc8d357c386b27a0da6cc9ffda9
https://doi.org/10.1111/j.1439-0507.1992.tb00812.x
https://doi.org/10.1111/j.1439-0507.1992.tb00812.x
Autor:
M. Koster, J Daunas, R Legendre, K De Beule, E Chwetzoff, P. De Doncker, N Blatchford, Geert Cauwenbergh
Publikováno v:
Mycoses. 31:476-485
Summary: A total of 137 patients with aspergillosis or aspergilloma has been treated with 50 to 400 mg itraconazole daily during 11 to 780 days. The global assessments »markedly improved« and »cured« were given to 60% of the treatments in invasiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd7acd255227e51afa02ee9a658640a7
https://doi.org/10.1111/j.1439-0507.1988.tb03653.x
https://doi.org/10.1111/j.1439-0507.1988.tb03653.x
Autor:
T. De Marez, C. Reddy, R. F. Patientia, Andreas H. Diacon, Peter R. Donald, J. Allen, K. De Beule, D. F. McNeeley, Thuli Mthiyane, R. Kerstens, Roxana Rustomjee, Anil Koul, Venter A, R. van Heeswijk
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:2831-2835
Tibotec Medicinal Compound 207 (TMC207) is a novel diarylquinoline with a unique mode of action that targets mycobacterial ATP synthase. TMC207 exhibits high in vitro activity against mycobacterial strains either susceptible or resistant to all first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69dccd7862365e5b63fe8605a5415070
https://doi.org/10.1128/aac.01204-07
https://doi.org/10.1128/aac.01204-07
Publikováno v:
Antimicrobial Agents and Chemotherapy, 50, 12, pp. 4096-102
Antimicrobial Agents and Chemotherapy, 50, 4096-102
Antimicrobial Agents and Chemotherapy, 50, 4096-102
Contains fulltext : 50982.pdf (Publisher’s version ) (Closed access) Originally, itraconazole for parenteral administration was licensed in a 40% hydroxypropyl-beta-cyclodextrin (HPBCD) solution for intravenous administration. A novel formulation,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaff70564426e870a5d724c368a08f48
https://hdl.handle.net/2066/50982
https://hdl.handle.net/2066/50982
Publikováno v:
Clinical Infectious Diseases. 33:e83-e90
The pharmacokinetics, efficacy, and safety of intravenous (iv) itraconazole (2 days at 400 mg/day, 12 days at 200 mg/day), followed by 12 weeks of oral capsules (400 mg/day) were studied in 31 immunocompromised patients with pulmonary invasive asperg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779529a08fcdd8fb4520cb68a8e54fc9
https://doi.org/10.1086/323020
https://doi.org/10.1086/323020
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 26:159-169
Itraconazole is a triazole antifungal agent with a broad spectrum of activity. It is well tolerated and highly efficacious, particularly because its main metabolite, hydroxy-itraconazole, also has considerable antifungal activity. Two new formulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a7afb0838daed45038fee287f3cbc4f
https://doi.org/10.1046/j.1365-2710.2001.00338.x
https://doi.org/10.1046/j.1365-2710.2001.00338.x
Autor:
W. Seifert, M Peeters, Margaret Johnson, J Bell, K De Beule, Brian Gazzard, D Spencer, W Schlech, S Miller, S Tchamouroff, Don Smith, M Youle, G Frechette
Publikováno v:
HIV Medicine. 2:78-83
Objectives To determine whether systemic or deep fungal infections can be prevented, a double-blind, placebo-controlled, phase III trial of itraconazole prophylaxis was undertaken in HIV-infected patients. Methods HIV-1 infected patients with CD4 cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2fef3e2356f935486e616dd0984bf5d
https://doi.org/10.1046/j.1468-1293.2001.00060.x
https://doi.org/10.1046/j.1468-1293.2001.00060.x
Publikováno v:
Scopus-Elsevier
Antimicrobial agents and chemotherapy, Vol. 42, no. 2, p. 404-8 (1998)
Antimicrobial agents and chemotherapy, Vol. 42, no. 2, p. 404-8 (1998)
The safety, tolerability, and pharmacokinetics of an oral solution of itraconazole and its active metabolite hydroxyitraconazole were investigated in an open multicenter study of 26 infants and children aged 6 months to 12 years with documented mucos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ccfa09629889f21b57600fce234aca
https://doi.org/10.1128/aac.42.2.404
https://doi.org/10.1128/aac.42.2.404
Autor:
P Jaqmin, Johan Decruyenaere, Dirk Vogelaers, K Vandewoude, K Groen, R Woestenborghs, A Van Peer, K De Beule, Francis Colardyn
Publikováno v:
Antimicrobial Agents and Chemotherapy. 41:2714-2718
Pharmacokinetics and safety of a hydroxy-beta-propyl solution of itraconazole were assessed in 16 patients in an intensive care unit. On the first 2 days, four 1-h infusions of 200 mg were given at 0, 8, 24, and 32 h. From day 3 to 7, inclusive, a si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15994c5e2a404f51e060df55fa24033a
https://doi.org/10.1128/aac.41.12.2714
https://doi.org/10.1128/aac.41.12.2714
A double-blind vehicle-controlled study of R 68 151 in psoriasis: A topical 5-lipoxygenase inhibitor
Publikováno v:
Journal of the American Academy
Recently the pharmacologic role of leukotrienes (LTs), especially that of LTB4, has been intensively investigated in psoriasis. In vitro, R 68 151 is a potent 5-lipoxygenase inhibitor and consequently reduces LTB4 formation. Therefore the role of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::240e7cb7e04287854fd16fde80d48456
https://doi.org/10.1016/0190-9622(90)70103-o
https://doi.org/10.1016/0190-9622(90)70103-o